Ireland based drug maker Allergan (NYSE: AGN) on Friday said it has agreed to jointly develop and market a trial drug combining aztreonam and avibactam to treat serious infections, with Anglo-Swedish drug major AstraZeneca (LSE: ANZ).
No financial details were disclosed. Under the terms of the deal, Allergan will maintain marketing rights for the product in the USA and Canada and AstraZeneca will maintain commercialization rights in all other countries.
David Nicholson, executive vice president, Allergan, said: "The rate of antibiotic resistance continues to increase worldwide, representing a truly global threat that requires collaboration and sustained commitment from industry and government to develop solutions. As a leader in anti-infectives, we are dedicated to the ongoing research and development of innovative products, like ATM-AVI, for patients with difficult-to-treat infections who, today, have very few or no effective options."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze